Prochlorperazine inhalation - Alexza Pharmaceuticals
Alternative Names: AZ-001; Staccato prochlorperazineLatest Information Update: 15 Dec 2025
At a glance
- Originator Alexza Pharmaceuticals
- Class Antiemetics; Antipsychotics; Phenothiazines; Piperazines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 11 Dec 2025 Lee's Pharmaceutical acquires Staccato® One Breath Technology® platform and assets including intellectual property, know-how, trademarks, product pipeline, equipment, products and access to GMP facility from Alexza Pharmaceuticals
- 20 Nov 2009 Prochlorperazine is still available for partnering (http://www.alexza.com)
- 26 Mar 2007 Final efficacy and adverse events data from a phase IIb trial migraine released by Alexza Pharmaceuticals